CSC Gets Follow-on Healthcare Contract Worth Up To $90 Mln - Quick Facts

(RTTNews) - Computer Sciences Corp. (CSC) said that its DynPort Vaccine Company LLC or DVC has received a follow-on contract to continue supporting the National Institute of Allergy and Infectious Diseases or NIAID, part of the National Institutes of Health.

The contract, valued at up to $90 million, is a 10-year Indefinite Delivery/Indefinite Quantity contract to support and conduct Phase 1 clinical trials of infectious disease therapeutics.

Under the agreement, DVC and its teaming partners, Quintiles, Health Decisions and WCCT Global, will support and manage the Phase 1 clinical trial units to assess the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties, which will inform appropriate human dosing regimens.

As the prime contractor, DVC will manage the overall program and clinical operations, quality assurance and co-development of protocols and concepts.